Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 2.34 [1.33, 4.14]
Studies not reported
Moderate
Withdrawals due to adverse events · acute gout
NSAIDs showed no clear difference in withdrawals due to adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 2.8 [0.55, 14.22]
Studies not reported
Moderate
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · UC patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · UC patients
1 finding from 1 review
Withdrawals due to adverse events · UC patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · participants with normal or abnormal lipid profiles
It is very uncertain whether all doses of cerivastatin changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found